Related Experiment Video

Updated: Jul 9, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

[A case of therapy-related acute myeloid leukemia associated with inv(16)]

So-Young Lee1, Myungshin Kim, Jihyang Lim

  • 1Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.

The Korean Journal of Laboratory Medicine
|December 21, 2007
PubMed

Insights

Therapy-related acute myeloid leukemia (t-AML) with the inv(16) chromosomal abnormality is rare. This case highlights t-AML with inv(16) following ovarian cancer chemotherapy.

Area of Science:

  • Hematology
  • Oncology
  • Cytogenetics

Background:

  • inv(16)(p13q22) is a known genetic alteration in de novo acute myeloid leukemia (AML).
  • This abnormality is frequently associated with the French-American-British (FAB) M4eo subtype.
  • Therapy-related AML (t-AML) with inv(16) is exceptionally uncommon in medical literature.

Observation:

  • A patient diagnosed with ovarian serous cystadenocarcinoma received combination chemotherapy.
  • The treatment regimen included an antimitotic agent and an alkylating agent (cisplatin-paclitaxel).
  • Following treatment, the patient developed t-AML.

Findings:

  • The developed t-AML exhibited the inv(16)(p13q22) chromosomal abnormality.
  • This represents a rare occurrence of inv(16) in the context of therapy-related AML.
  • The patient's prior ovarian cancer treatment is implicated in the development of this specific AML subtype.

Implications:

  • This case expands the understanding of secondary genetic alterations in t-AML.
  • It suggests a potential link between specific chemotherapy agents and the induction of inv(16) in AML.
  • Further research is warranted to explore the mechanisms and frequency of this association.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...